NCT03651635View on ClinicalTrials.gov

MR-proADM and CT-proET-1 During ICU Treatment

CompletedOBSERVATIONAL
Enrollment

533

Participants

Timeline

Start Date

January 8, 2018

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Acute Phase BiomarkersMedical ICU Admitted Patients
Interventions
DIAGNOSTIC_TEST

Blood sampling for MR-proADM & CT-proET-1

Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM \& CT-proET-1

Trial Locations (1)

8091

University Hospital Zurich, Medical intensive care unit, Zurich

All Listed Sponsors
collaborator

ThermoFisher Scientific Brahms Biomarkers France

INDUSTRY

lead

University of Zurich

OTHER

NCT03651635 - MR-proADM and CT-proET-1 During ICU Treatment | Biotech Hunter | Biotech Hunter